Accelerated osteoclastic bone resorption has a central role in the pathogenesis of osteoporosis and other bone diseases. Identifying the molecular pathways that regulate osteoclast activity provides a key to understanding the causes of these diseases and to the development of new treatments. Here we show that mice with inactivation of cannabinoid type 1 (CB 1 ) receptors have increased bone mass and are protected from ovariectomy-induced bone loss. Pharmacological antagonists of CB 1 and CB 2 receptors prevented ovariectomy-induced bone loss in vivo and caused osteoclast inhibition in vitro by promoting osteoclast apoptosis and inhibiting production of several osteoclast survival factors. These studies show that the CB 1 receptor has a role in the regulation of bone mass and ovariectomy-induced bone loss and that CB 1 -and CB 2 -selective cannabinoid receptor antagonists are a new class of osteoclast inhibitors that may be of value in the treatment of osteoporosis and other bone diseases.
Accelerated osteoclastic bone resorption has a central role in the pathogenesis of osteoporosis and other bone diseases. Identifying the molecular pathways that regulate osteoclast activity provides a key to understanding the causes of these diseases and to the development of new treatments. Here we show that mice with inactivation of cannabinoid type 1 (CB 1 ) receptors have increased bone mass and are protected from ovariectomy-induced bone loss. Pharmacological antagonists of CB 1 and CB 2 receptors prevented ovariectomy-induced bone loss in vivo and caused osteoclast inhibition in vitro by promoting osteoclast apoptosis and inhibiting production of several osteoclast survival factors. These studies show that the CB 1 receptor has a role in the regulation of bone mass and ovariectomy-induced bone loss and that CB 1 -and CB 2 -selective cannabinoid receptor antagonists are a new class of osteoclast inhibitors that may be of value in the treatment of osteoporosis and other bone diseases.
Osteoclasts are cells derived from the monocyte-macrophage lineage that have an important role in modeling bone during skeletal growth and in remodeling bone during adult life 1 . Increased osteoclast activity or uncoupling of osteoclastic bone resorption from bone formation results in focal or generalized bone loss and is a characteristic feature of bone diseases such as osteoporosis, Paget disease of bone and cancer-associated bone disease 2 . The importance of osteoclastic bone resorption in the pathogenesis of these diseases is reflected by the fact that the most successful drug treatments for bone disease work by inhibiting bone resorption 3 . Osteoclastic bone resorption is regulated by a complex interplay between circulating calciotropic hormones like parathyroid hormone, calcitriol and sex hormones, and local regulators of bone cell activity like receptor activator of nuclear factor κB ligand (RANKL), macrophage colony-stimulating factor (M-CSF) and osteoprotegerin 4 . Recent work has shown that neuroendocrine pathways and neurotransmitters also have a key role in the regulation of bone remodeling [5] [6] [7] [8] [9] . In view of this, we investigated the role of the endocannabinoid system in the regulation of bone mass and bone turnover by studying the skeletal phenotype in mice with targeted inactivation of CB 1 receptors (CB 1 knockout mice) and by studying the effects of cannabinoid receptor ligands on bone cell function in vitro and ovariectomy-induced bone loss in vivo.
RESULTS

Skeletal phenotype of CB 1 knockout mice
We found that CB 1 knockout mice had significantly increased bone mineral density (BMD) when compared with wild-type littermates. For example, the levels of BMD assessed by dual X-ray absorptiometry at the femur were 18% higher (P < 0.001) in CB 1 knockout animals than wild-type and values at the spine were 10% higher (P < 0.02; Fig. 1a) . Further evaluation using peripheral quantitative computed tomography showed that trabecular BMD values at the tibial metaphysis in CB 1 knockout mice were 16% higher than in wild-type (P < 0.001; Fig. 1b) and this difference was clearly evident on lowpower photomicrographs at this site (Fig. 1c) . Bone histomorphometry showed that CB 1 knockout mice had significantly increased trabecular bone volume at the tibial metaphysis compared with wildtype mice (P < 0.001), consistent with the BMD measurements, but no difference was observed between CB 1 knockout mice and wildtype littermates in terms of osteoclast numbers, eroded surfaces or osteoblast numbers (Supplementary Table 1 online). This indicates that absence of the CB 1 receptor regulates BMD but does not influence bone turnover appreciably in normal adult mice. To determine whether the CB 1 receptor has a role in the regulation of bone loss, we studied the effects of ovariectomy in CB 1 knockout and wild-type mice. We found that CB 1 knockout mice were completely resistant to trabecular bone loss induced by ovariectomy when compared with wild-type; analysis by peripheral quantitative computed tomography showed no significant change in total BMD of the tibial metaphysis in CB 1 knockout mice after ovariectomy, compared with a 12% reduction in wild-type (P < 0.01; Fig. 2a) . Analysis by microcomputed tomography showed a 40% reduction in trabecular bone volume after ovariectomy in wild-type mice (P < 0.001; Fig. 2b ), a 12% reduction in trabecular thickness (P < 0.05; Fig. 2c ) and a 30% reduction in trabecular number (P < 0.01; Fig. 2d ), whereas none of these variables changed significantly in CB 1 knockout mice. Uterine weight (mean ± s.d.) fell to a similar degree after ovariectomy in wild-type mice (0.38 ± 0.03 versus 0.08 ± 0.01 g; P < 0.01) and CB 1 knockout mice (0.43 ± 0.02 versus 0.09 ± 0.01 g; P < 0.01). These data indicate that the CB 1 receptor has an essential role in regulating the bone loss that results from estrogen deficiency, but that the gonadal response to ovariectomy is unaffected by CB 1 deficiency.
Effects of cannabinoid receptor ligands on osteoclast function
To explore the mechanisms by which the CB 1 pathway regulates bone mass and bone loss, we studied the effects of various cannabinoid receptor agonists and antagonists on bone cell function in vitro using primary mouse osteoblast cultures and RANKL-generated mouse osteoclast cultures. None of the cannabinoid ligands that we tested significantly affected osteoblast growth or viability at concentrations of up to 20 µM (data not shown), but we did observe significant effects on osteoclast activity when we used ligand concentrations in the nanomolar range. The CB 1 -selective antagonist AM251 (ref. 10) and the CB 2 -selective antagonists SR144528 and AM630 (ref. 10) significantly inhibited osteoclast formation in RANKL-and M-CSF-stimulated mouse bone marrow cultures in a concentration-dependent manner with 50% inhibition at 700 nM for AM251, 850 nM for SR144528 and 100 nM for AM630 (P < 0.05; Fig. 3a) . Conversely, the endogenous cannabinoid receptor agonist anandamide and the nonselective synthetic agonist CP55940 stimulated osteoclast formation in a concentration-dependent manner between 100 nM and 5 µM (Fig. 3a) . Representative photomicrographs from cultures treated with vehicle, anandamide, AM251 and SR144528 are shown in Fig. 3b . Moreover, anandamide reversed the inhibitory effect of AM251 on osteoclast formation (Fig. 3c) , consistent with a receptor-mediated effect.
Functional role of CB 1 and CB 2 receptors on osteoclasts Both the CB 1 and CB 2 receptor subtypes were expressed on mouse osteoclasts as assessed by immunohistochemical staining, western blotting and RT-PCR ( Supplementary Fig. 1 online) , indicating that CB 1 , CB 2 or both receptors could mediate the effects of cannabinoid ligands on osteoclast activity. To clarify the relative role of the CB 1 and CB 2 receptors as targets for the regulation of osteoclast activity, we compared the effects of AM251 and AM630 on RANKL-induced osteoclast formation in cultures generated from CB 1 knockout mice and wild-type littermates. Cultures prepared from CB 1 knockout mice were resistant to the inhibitory effects of AM251 on osteoclast formation when compared with wild-type cultures (Fig. 4a) . The CB 2 -selective antagonist AM630 inhibited osteoclast formation to a similar extent in cultures prepared from CB 1 knockout and wild-type mice and was an order of magnitude more potent than AM251 (Fig. 4b) . Taken together, these data indicate that the CB 1 receptor contributes in part to the osteoclast inhibition that occurs in vitro when these cultures are exposed to cannabinoid antagonists, but that osteoclast inhibition can also occur through antagonism of CB 2 receptors.
Effects of cannabinoid antagonists on bone loss
As CB 1 knockout mice were resistant to ovariectomy-induced bone loss, we wanted to determine whether pharmacological blockade of cannabinoid receptors could prevent the bone loss that occurs as the result of ovariectomy. We studied the effects of AM251 in doses of 0.3-3.0 mg/kg/d on ovariectomy-induced bone loss in wild-type mice and SR144528 at a single dose of 3 mg/kg/d. These doses were chosen on the basis of previous work, which has shown that AM251 and the related compound SR141716 prevent diet-induced obesity in wild-type mice in doses of 3-30 mg/kg/d [11] [12] [13] . We found that AM251 protected against ovariectomy-induced bone loss in a concentration-dependent manner at doses as low as 0.3 mg/kg/d (Fig. 5a-c) . Bone histomorphometry showed that osteoclast numbers and active resorption surfaces were increased after ovariectomy in vehicle-treated animals, whereas no significant increase in either variable was observed in AM251-treated animals (Supplementary Table 2 online). Osteoblast numbers were unaffected by AM251 treatment, indicating that the protective effect of cannabinoid receptor blockade on ovariectomy-induced bone loss was primarily mediated by inhibiting bone resorption rather than by stimulating bone formation. Administration of SR144528 to ovariectomized mice in a dose of 3 mg/kg/d also completely prevented ovariectomyinduced bone loss, with results almost identical to those observed with AM251 at 3 mg/kg/d (data not shown).
Effects of cannabinoid ligands on osteoclast apoptosis
We investigated the molecular mechanisms by which cannabinoid receptor blockade inhibits bone resorption, by studying the effects of cannabinoid receptor antagonists on apoptosis and key intracellular signaling pathways involved in osteoclast survival using purified rabbit osteoclasts and RANKL-generated mouse osteoclasts. We found that AM251 and SR144528 stimulated apoptosis of rabbit and mouse osteoclasts by 12-17-fold above control values ( Supplementary Fig. 2 online), as detected by deoxynucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) and typical changes in nuclear morphology on DAPI-stained cultures ( Supplementary Fig. 2 online) . Activation of caspase 3 was observed in both rabbit and mouse osteoclasts that were exposed to cannabinoid antagonists ( Supplementary Fig. 2 online), and this was accompanied by a reduction in osteoclast numbers and inhibition of bone resorption ( Supplementary Fig. 2 online) . The only considerable difference between the response of mouse and rabbit osteoclasts to cannabinoid antagonists was that maximal stimulation of apoptosis occurred at 2 µM in mouse osteoclasts compared with 10 µM in rabbit osteoclasts, presumably because of differences among the species in affinity of the receptors for the ligands tested. We also investigated the effects of AM251 on activation of key survival factors in osteoclasts, including extracellular signal-regulated kinase (ERK), the p65 component of NF-κB, NFATc1; c-jun and c-fos [14] [15] [16] . These studies showed that AM251 at a concentration of 2 µM abolished RANKL-induced ERK phosphorylation (Fig. 6a) and significantly inhibited RANKL-induced nuclear translocation and DNA binding of NFATc1, c-jun and c-fos (P < 0.001; Fig. 6b-d) . In contrast, AM251 did not inhibit RANKL-induced NF-κB (p65) activation in this assay (data not shown).
DISCUSSION
The studies presented here indicate that the CB 1 receptor has a hitherto unrecognized role in the regulation of bone mass and bone loss resulting from estrogen deficiency. Adult CB 1 knockout mice had substantially higher BMD than wild-type littermates at several skeletal sites and CB 1 knockout mice were completely protected against ovariectomy-induced bone loss. The synthetic cannabinoid receptor antagonists AM251, SR144528 and AM630 inhibited osteoclast formation and bone resorption in vitro, and both AM251 and SR144528 protected against ovariectomy-induced bone loss in vivo by inhibiting osteoclastic bone resorption. Conversely, the endogenous cannabinoid agonist anadamide and the synthetic agonist CP55940 enhanced osteoclast formation in vitro, and anadamide reversed the inhibitory effects of AM251 osteoclast formation, consistent with a receptor-mediated effect. Osteoclasts generated from CB 1 knockout mice were resistant to the inhibitory effects of AM251 compared with wild-type mice, consistent with the hypothesis that the osteoclast inhibition we observed with cannabinoid antagonists was mediated, in part, by the CB 1 receptor. We also gained evidence to show CB 2 receptor-mediated osteoclast inhibition can also occur in vitro, from the observation that the CB 2 -selective antagonist AM630 inhibited osteoclast formation equally well in cultures prepared from CB 1 knockout and wild-type mice. The inhibitory effects on osteoclast formation that we observed at high AM251 concentrations (>1,000 nM) in CB 1 knockout cultures were probably attributable to blockade of the CB 2 receptor by this compound 10 . The extent to which CB 1 versus CB 2 receptors contributed to the prevention of the ovariectomy-induced bone loss that we observed with cannabinoid antagonist treatment in vivo remains to be determined, as does the relative contribution of central versus peripheral cannabinoid receptors in mediating this effect. Further work will also be required to determine whether the inhibitory effects we observed were the result of antagonism of the action of endogenous cannabinoid receptor ligands or to inverse agonism, given that AM630, AM251 and SR144528 have all been shown to elicit effects at cannabinoid receptors that are opposite to those produced by cannabinoid agonists, even in the absence of agonist binding 17 . The mechanism of osteoclast inhibition resulting from cannabinoid receptor blockade was probably the result of osteoclast apoptosis, because AM251 and SR144528 markedly enhanced apoptosis of mature rabbit osteoclasts and of RANKL-generated mouse osteoclasts. Exposure of mouse osteoclasts to AM251 blocked RANKLinduced ERK phosphorylation and prevented activation of several key osteoclast stimulatory factors including NFATc1, phosphorylated c-jun and c-fos. Notably, however, AM251 had no inhibitory effect on NF-κB activation, suggesting that cannabinoid receptor antagonists may cause osteoclast inhibition through the ERK-AP1 pathway rather than the NF-κB pathway.
The phenotype that we observed in CB 1 knockout mice indicates that the CB 1 receptor has an essential role in regulating BMD and bone loss that results from estrogen deficiency. Furthermore, the pharmacological studies in vitro show that the CB 1 and CB 2 receptors may have overlapping functions in the regulation of osteoclast activity. Further studies of the skeletal phenotype in CB 2 knockout mice will be required to fully evaluate the role of the CB 2 receptor subtype on bone metabolism and osteoclast function in vivo.
The results of our studies are important because we have shown that pharmacological antagonists of cannabinoid receptors represent a new class of osteoclast inhibitors, whereas cannabinoid receptor agonists act as stimulators of bone resorption. This suggests that cannabinoid receptor antagonists may represent a promising new class of antiresorptive drugs for the treatment of osteoporosis and other bone diseases associated with increased osteoclast activity. Our data also raise the possibility that recreational or therapeutic use of cannabis derivatives that act as agonists at cannabinoid receptors might enhance bone loss and predispose to osteoporosis.
METHODS
Cell culture. We generated mouse osteoclast cultures by isolating mononuclear cells from the bone marrow of mouse long bones, essentially as previously described 18 . The cells were cultured in αMEM with 10% FCS and M-CSF (100 ng/ml) for 3 d. We collected adherent cells and plated them at 0.5 × 10 4 cells/well in 96-well plates in 125 µl of αMEM supplemented with 10% FCS, M-CSF (25 ng/ml) and RANKL (100 ng/ml) for 4 d. We added test substances on day 7 and terminated the cultures on day 10. Rabbit osteoclast cultures were performed as described 19 and exposed to test substances for 48 h. We assessed osteoclast formation was assessed by counting tartrate-resistant acid phosphatase-positive multinucleated cells and bone resorption by measuring resorption pit area using reflected light microscopy as described 20 . Apoptosis was detected by the characteristic changes in nuclear morphology after 4,6-diamidino-2-phenylinole (DAPI) staining as previously described 20 , and by detection of fragmented DNA by terminal deoxynucleotidyl transferasemediated dUTP nick end labeling using the ApopTag Plus Fluorescein In Situ Apoptosis Detection Kit (Intergen). We counted cells with clearly fragmented DNA or positive ApopTag labeling and expressed their number as a percentage of total cell number.
Immunofluorescence. We performed immunofluorescent staining of mouse osteoclasts for cannabinoid receptors using a rabbit antibody to the CB 1 receptor 21 (Caymen Chemical) and a rabbit antibody to the CB 2 receptor 22 (Caymen Chemical) followed by Alexa Fluor 488 goat antibody specific for rabbit IgG (Molecular Probes). Controls were performed by omitting the primary antibody. We identified osteoclasts by dual labeling with a mouse CD61-specific antibody directed against the vitronectin receptor (Pharmagen) followed by Alexa Fluor 594 goat antibody specific for mouse IgG.
Western blotting. We detected levels of intact (p-30) and activated (cleaved, p-19) caspase 3 by western blotting using a goat polyclonal antibody specific for caspase 3 (Santa Cruz), and a rabbit polyclonal antibody specific for cleaved caspase 3 (Cell Signalling Technology). We detected native and phosphorylated ERK by western blotting using antibodies to ERK and phosphorylated ERK (Cell Signalling Technology). We detected CB 1 and CB 2 receptors by western blotting using the same primary antibodies as for immunofluorescence, with an antirabbit secondary antibody linked to horseradish peroxidase (Caymen Chemical). We developed the chemiluminescent signal using SuperSignal (Pierce).
Molecular biology.
We assessed activation and DNA binding of NFATc1, NF-κB (p65), phosphorylated c-jun and c-fos by analysis of nuclear extracts using TRANS-AM transcription factor assay kits (Active Motif). We detected CB 1 and CB 2 receptor mRNA with RT-PCR using Qiagen Quantitect custom primers for the CB 1 receptor were: 5′-CCTTGCAGATACAACCTT-3′ and 5′-TGCCATGTCTCCTTTGATA-3′; predicted product size, 94 bp. For the CB 2 receptor, they were: 5′-CATAAGCCGATCTCTCCAA-3′ and 5′-CCAAAGCTGGTGCAGGAA-3′; predicted product size, 82 bp. The PCR protocol consisted of an initial incubation at 95 °C for 15 min., followed by 40 cycles of 94 °C for 15 s, 56 °C for 30 s and 76 °C for 30 s. All reactions were run with no template and no reverse transcription controls.
Drugs.
We dissolved all compounds in dimethylsulfoxide and added them to the cultures such that the final concentrations in all mixtures was 0.1%. We treated control cultures with dimethylsulfoxide alone at the same concentrations. AM251 and AM630 were obtained from Tocris. We synthesized SR144528 by coupling of 1-(4-methylbenzyl)-5-(4-chloro-3-methylphenyl)pyrazole-3-carboxylic acid chloride and (1S)-2-endo,exo-amino-1,3,3-trimethylbicyclo [2.2.1]heptane. We verified the identity and purity of SR144528 using nuclear magnetic resonance spectroscopy.
Animals.
Animal experiments were approved by the ethical review board of the University of Aberdeen and were conducted in accordance with UK Home Office regulations. The strain of CB 1 knockout mice and wild-type littermates used in this study were as previously described 23 . We also performed experiments using C57BL/6 mice obtained from Harlan Laboratories. We performed ovariectomy or sham ovariectomy in 9-week-old adult female mice as previously described 24 . Treatment with AM251 and SR144528 was commenced 2 d after ovariectomy or sham ovariectomy by intraperitoneal administration of the drug in corn oil. Controls received corn oil alone. We continued the treatment for 19 d and terminated the experiment on day 21. We studied eight mice per group. Bone mineral density was measured by dual X-ray absorptiometry at the spine and femur using a PIXIMUS scanner; and at the tibial metaphysis by peripheral quantitative computed tomography using a Stratec Research M scanner or by microcomputed tomography, using a Skyscan 1072 scanner. After BMD scanning, we embedded the limbs and processed them for bone histomorphometry as previously described 24 .
Statistics. Between-group comparisons were by ANOVA with Dunnet post-test. The concentrations at which 50% inhibition occurred were calculated from concentration response curves using the GraphPad PRISM computer program (GraphPad Software). 
